Protagonist and Takeda Present 52-Week Results of Rusfertide Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 06 2025
0mins
Source: Newsfilter
- Sustained Efficacy: In the VERIFY study, 61.9% of patients maintained a clinical response without phlebotomy eligibility at 52 weeks, demonstrating rusfertide's long-term effectiveness in treating polycythemia vera, which could redefine current treatment standards.
- Good Safety Profile: Rusfertide's safety over 52 weeks was consistent with prior observations, with injection site reactions occurring in 47.4% of patients, indicating good tolerability that supports long-term use in patients.
- Significant Reduction in Phlebotomy Needs: In the THRIVE study, rusfertide reduced the annual phlebotomy rate from 9.2 to 0.7, achieving a 13-fold decrease that significantly enhances patient quality of life and lowers thrombotic risks.
- Clinical Decision Support: The study results will be presented at the American Society of Hematology annual meeting, further supporting rusfertide's potential as a new treatment option for polycythemia vera, expected to advance the NDA submission process to the FDA.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PTGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PTGX
Wall Street analysts forecast PTGX stock price to fall
13 Analyst Rating
12 Buy
1 Hold
0 Sell
Strong Buy
Current: 96.660
Low
65.00
Averages
94.54
High
115.00
Current: 96.660
Low
65.00
Averages
94.54
High
115.00
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on peptide therapeutics. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The Company also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rusfertide Shows Significant Improvements in Patient Outcomes for Polycythemia Vera in Pivotal Study
- Clinical Response Rate Increase: In the Phase 3 VERIFY study, the combination of Rusfertide and standard care more than doubled clinical response rates, exceeding 50%, indicating its significant potential in treating polycythemia vera.
- Good Safety and Tolerability: Rusfertide demonstrated good tolerability over 52 weeks, with injection site reactions at 47.4% and serious adverse events at only 8.1%, laying a solid foundation for its future market introduction.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for Rusfertide and granted Priority Review, with a decision expected in Q3 2024, which will expedite its market entry and address the urgent need for new therapies.
- Strengthened Partnership: The global licensing and collaboration agreement between Takeda and Protagonist will drive the commercialization of Rusfertide, enhancing both companies' ability to meet the treatment needs of patients with polycythemia vera.
See More
Protagonist Therapeutics Reports Q4 Earnings Miss
- Earnings Miss: Protagonist Therapeutics reported a Q4 GAAP EPS of -$0.69, missing expectations by $0.20, indicating challenges in profitability that may affect investor confidence.
- Revenue Performance: The company generated $7.44M in revenue for Q4, which, while showing some growth, fails to offset the earnings shortfall, potentially raising concerns about future growth prospects in the market.
- Cash Reserves Increase: As of December 31, 2025, Protagonist's cash, cash equivalents, and marketable securities totaled $646.0M, a 15.5% increase from $559.2M the previous year, demonstrating improved financial management.
- Market Dynamics Shift: ClearBridge Small-Cap Growth trimmed its investments in Duolingo and Biohaven while adding PTGX in Q4, reflecting a rising interest in Protagonist despite its poor financial performance.
See More
BVF Fully Exits Protagonist Therapeutics with $170.12 Million Sale
- Full Exit: BVF's SEC filing on February 17, 2026, reveals a complete liquidation of its stake in Protagonist Therapeutics, selling 2,560,916 shares for approximately $170.12 million, indicating a reassessment of the company's future growth potential.
- Market Performance: As of February 17, 2026, Protagonist Therapeutics' stock price stood at $82.46, reflecting a 120% increase over the past year, significantly outperforming the S&P 500's 13% gain, showcasing positive market sentiment towards its New Drug Application.
- Strategic Shift: BVF's exit aligns with Protagonist's recent NDA submission, highlighting the importance of disciplined capital allocation and risk management as clinical-stage biotech firms reach critical milestones.
- Future Outlook: If rusfertide receives approval and reshapes polycythemia vera treatment, Protagonist's fundamentals will drive its value, but post-NDA, market expectations may reset, necessitating investor attention on subsequent developments.
See More
Protagonist Therapeutics Executive Executes Large Stock Sale
- Transaction Overview: On February 6, 2026, Protagonist Therapeutics director William D. Waddill exercised stock options and sold 20,000 shares for approximately $1.7 million, reflecting strong confidence in the company's stock.
- Scale of Sale Analysis: This sale is five times larger than the recent median sell transaction of 4,000 shares, indicating Waddill's previous cautious trading behavior, which may raise market concerns about his motivations.
- Market Performance Context: The transaction occurred during a period of strong stock performance, with shares closing at $84.49 on February 6, up from the sale price of $83.68, reflecting positive market expectations for Protagonist.
- Investor Focus: While Waddill's sale raises questions, Wall Street analysts generally rate Protagonist as a
See More
Protagonist Therapeutics CMO Sells Shares in Major Transaction
- Executive Stock Sale: Protagonist Therapeutics' Chief Medical Officer Arturo Molina sold 9,514 shares on January 20, 2026, for approximately $784,700, marking his largest direct market sale to date, surpassing his previous maximum of 2,712 shares, indicating confidence in the market.
- Shareholding Status: Post-transaction, Molina retains 97,266 shares valued at $8.11 million, demonstrating his ongoing investment in the company, although the sale was primarily for tax withholding purposes.
- Company Financial Overview: Protagonist Therapeutics boasts a market capitalization of $5.11 billion, with a 120.48% stock price increase over the past year, reflecting strong market expectations for future growth, particularly as it expands its clinical trial pipelines.
- Analyst Rating Support: While Molina's sale should not influence investment decisions, the majority of Wall Street analysts rate the company as a “strong buy,” and its high price-to-earnings ratio of 113.68 suggests optimistic growth expectations from the market.
See More
Protagonist Therapeutics Executive Sells Shares
- Executive Sell-off: Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, sold 9,514 shares on January 20, 2026, generating approximately $784,700 at a price of $82.48 per share, reducing his holdings from 106,780 to 97,266 shares, representing an 8.91% decrease.
- Market Reaction Analysis: Although Molina's sale was primarily for tax withholding purposes, the majority of Wall Street analysts rate Protagonist's stock as a 'strong buy', with a high price-to-earnings ratio of 113.68, indicating strong growth expectations from the market.
- Clinical Trial Progress: At the early January 2026 J.P. Morgan Healthcare Conference, Protagonist highlighted significant expansion in its clinical trial pipelines, particularly with two key pharmaceutical products reaching advanced clinical development stages, backed by major firms like Johnson & Johnson.
- Stock Performance Review: Protagonist's stock soared approximately 123% in 2025, and with robust support from Wall Street and institutional investors, it appears to be an ideal option for those seeking portfolio exposure in the medical field.
See More
Rusfertide Shows Significant Improvements in Patient Outcomes for Polycythemia Vera in Pivotal Study
- Clinical Response Rate Increase: In the Phase 3 VERIFY study, the combination of Rusfertide and standard care more than doubled clinical response rates, exceeding 50%, indicating its significant potential in treating polycythemia vera.
- Good Safety and Tolerability: Rusfertide demonstrated good tolerability over 52 weeks, with injection site reactions at 47.4% and serious adverse events at only 8.1%, laying a solid foundation for its future market introduction.
- FDA Priority Review: The U.S. FDA has accepted the New Drug Application for Rusfertide and granted Priority Review, with a decision expected in Q3 2024, which will expedite its market entry and address the urgent need for new therapies.
- Strengthened Partnership: The global licensing and collaboration agreement between Takeda and Protagonist will drive the commercialization of Rusfertide, enhancing both companies' ability to meet the treatment needs of patients with polycythemia vera.
See More
Protagonist Therapeutics Reports Q4 Earnings Miss
- Earnings Miss: Protagonist Therapeutics reported a Q4 GAAP EPS of -$0.69, missing expectations by $0.20, indicating challenges in profitability that may affect investor confidence.
- Revenue Performance: The company generated $7.44M in revenue for Q4, which, while showing some growth, fails to offset the earnings shortfall, potentially raising concerns about future growth prospects in the market.
- Cash Reserves Increase: As of December 31, 2025, Protagonist's cash, cash equivalents, and marketable securities totaled $646.0M, a 15.5% increase from $559.2M the previous year, demonstrating improved financial management.
- Market Dynamics Shift: ClearBridge Small-Cap Growth trimmed its investments in Duolingo and Biohaven while adding PTGX in Q4, reflecting a rising interest in Protagonist despite its poor financial performance.
See More
BVF Fully Exits Protagonist Therapeutics with $170.12 Million Sale
- Full Exit: BVF's SEC filing on February 17, 2026, reveals a complete liquidation of its stake in Protagonist Therapeutics, selling 2,560,916 shares for approximately $170.12 million, indicating a reassessment of the company's future growth potential.
- Market Performance: As of February 17, 2026, Protagonist Therapeutics' stock price stood at $82.46, reflecting a 120% increase over the past year, significantly outperforming the S&P 500's 13% gain, showcasing positive market sentiment towards its New Drug Application.
- Strategic Shift: BVF's exit aligns with Protagonist's recent NDA submission, highlighting the importance of disciplined capital allocation and risk management as clinical-stage biotech firms reach critical milestones.
- Future Outlook: If rusfertide receives approval and reshapes polycythemia vera treatment, Protagonist's fundamentals will drive its value, but post-NDA, market expectations may reset, necessitating investor attention on subsequent developments.
See More
Protagonist Therapeutics Executive Executes Large Stock Sale
- Transaction Overview: On February 6, 2026, Protagonist Therapeutics director William D. Waddill exercised stock options and sold 20,000 shares for approximately $1.7 million, reflecting strong confidence in the company's stock.
- Scale of Sale Analysis: This sale is five times larger than the recent median sell transaction of 4,000 shares, indicating Waddill's previous cautious trading behavior, which may raise market concerns about his motivations.
- Market Performance Context: The transaction occurred during a period of strong stock performance, with shares closing at $84.49 on February 6, up from the sale price of $83.68, reflecting positive market expectations for Protagonist.
- Investor Focus: While Waddill's sale raises questions, Wall Street analysts generally rate Protagonist as a
See More
Protagonist Therapeutics CMO Sells Shares in Major Transaction
- Executive Stock Sale: Protagonist Therapeutics' Chief Medical Officer Arturo Molina sold 9,514 shares on January 20, 2026, for approximately $784,700, marking his largest direct market sale to date, surpassing his previous maximum of 2,712 shares, indicating confidence in the market.
- Shareholding Status: Post-transaction, Molina retains 97,266 shares valued at $8.11 million, demonstrating his ongoing investment in the company, although the sale was primarily for tax withholding purposes.
- Company Financial Overview: Protagonist Therapeutics boasts a market capitalization of $5.11 billion, with a 120.48% stock price increase over the past year, reflecting strong market expectations for future growth, particularly as it expands its clinical trial pipelines.
- Analyst Rating Support: While Molina's sale should not influence investment decisions, the majority of Wall Street analysts rate the company as a “strong buy,” and its high price-to-earnings ratio of 113.68 suggests optimistic growth expectations from the market.
See More
Protagonist Therapeutics Executive Sells Shares
- Executive Sell-off: Arturo Molina, Chief Medical Officer of Protagonist Therapeutics, sold 9,514 shares on January 20, 2026, generating approximately $784,700 at a price of $82.48 per share, reducing his holdings from 106,780 to 97,266 shares, representing an 8.91% decrease.
- Market Reaction Analysis: Although Molina's sale was primarily for tax withholding purposes, the majority of Wall Street analysts rate Protagonist's stock as a 'strong buy', with a high price-to-earnings ratio of 113.68, indicating strong growth expectations from the market.
- Clinical Trial Progress: At the early January 2026 J.P. Morgan Healthcare Conference, Protagonist highlighted significant expansion in its clinical trial pipelines, particularly with two key pharmaceutical products reaching advanced clinical development stages, backed by major firms like Johnson & Johnson.
- Stock Performance Review: Protagonist's stock soared approximately 123% in 2025, and with robust support from Wall Street and institutional investors, it appears to be an ideal option for those seeking portfolio exposure in the medical field.
See More
